<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30517259</article-id><article-id pub-id-type="pmc">6257536</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0152</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of del Nido Cardioplegia with Blood Cardioplegia in
Coronary Artery Bypass Grafting Combined with Mitral Valve
Replacement</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kavala</surname><given-names>Ali Aycan</given-names></name><role>MD</role><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Turkyilmaz</surname><given-names>Saygin</given-names></name><role>MD</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiovascular Surgery, Bakirkoy Dr. Sadi Konuk
Training and Research Hospital, Istanbul, Turkey.</aff><author-notes><corresp id="c1">Correspondence Address: Saygin Turkyilmaz, Department of
Cardiovascular Surgery, Bakirkoy Dr Sadi Konuk Training and Research Hospital,
Dr. Tevfik Saglam Cad, no: 11, Bakirkoy, Istanbul, Turkey, Zip code: 34147.
E-mail:<email>sygnty@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2018</year></pub-date><volume>33</volume><issue>5</issue><fpage>496</fpage><lpage>504</lpage><history><date date-type="received"><day>27</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To compare del Nido cardioplegia (DNC) with blood cardioplegia (BC) in
coronary artery bypass grafting (CABG) combined with mitral valve
replacement.</p></sec><sec><title>Methods</title><p>A 3-year single-center retrospective cohort study was carried out. Subjects
who underwent CABG (up to triple bypass) combined with mitral valve
replacement were divided into DNC and BC groups. Each group had thirty
subjects.</p></sec><sec><title>Results</title><p>Both groups demonstrated similar baseline characteristics, including age,
gender, cardiac/non-cardiac comorbidity, and preoperative echocardiographic
parameters. Compared with the BC group, the DNC group demonstrated
significantly lower cardioplegia volume (BC = 1130.00&#x000b1;194.1 mL, DNC =
884.33&#x000b1;156.8 mL, <italic>P</italic>=0.001), cardiopulmonary bypass
time (DNC = 110.90&#x000b1;12.52 min, BC = 121.70&#x000b1;13.57 min,
<italic>P</italic>=0.002), aortic clamp time (DNC = 91.37&#x000b1;11.58
min, BC = 101.37&#x000b1;13.87 min, <italic>P</italic>=0.004), and need for
intraoperative defibrillation (DNC = 6 events, BC = 21 events,
<italic>P</italic>=0.001). Postoperative creatine kinase-MB levels and
troponin levels were significantly lower in the DNC group than in the BC
group. Postoperative haemoglobin and haematocrit levels were significantly
higher in the DNC group than in the BC group. The intubation period (hours)
in intensive care unit (ICU) was significantly small in the BC group (DNC =
8.13&#x000b1;12.21, BC = 6.82&#x000b1;1.57, <italic>P</italic>=0.037);
however, ICU stay, total hospital stay, and postoperative complication rates
were not significantly different between them. At pre-discharge
echocardiography, the DNC group demonstrated significantly higher ejection
fraction rates than the BC group (47.79&#x000b1;5.50 and 45.72&#x000b1;5.86,
respectively, <italic>P</italic>=0.005).</p></sec><sec><title>Conclusion</title><p>DNC presented better intraoperative and postoperative parameters and it is an
effective and safe alternative to BC for CABG combined with mitral valve
replacement.</p></sec></abstract><kwd-group><kwd>Mitral Valve/Surgery</kwd><kwd>Coronary Artery Bypass</kwd><kwd>Heart Arrest, Induced</kwd><kwd>Cardioplegic Solutions</kwd><kwd>Treatment Outcome</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Blood cardioplegia</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">Htc</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Haematocrit </td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CK-MB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Creatine kinase-MB</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NCSS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Number Cruncher
Statistical System</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NYHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= New York Heart
Association</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DNC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Del Nido
cardioplegia</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RBCs</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Red blood cells</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ejection fraction</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard deviation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FFP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Fresh frozen plasma</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TIA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transient ischemic
attack</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1"> Hgb</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1"> = Haemoglobin</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Open cardiac procedures mostly require cardiopulmonary bypass (CPB) to maintain the
blood supply during surgery<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Cardioplegia is a state of cardiac arrest and cardiac
protection induced by the infusion of cardioplegia solution into the myocardium and
involves the cessation of myocardial contractions. During cardioplegia, ischaemia
occurs in myocardial tissue<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. After cross-clamp removal and reperfusion is initiated,
a degree of ischaemia/reperfusion injury occurs, which is responsible for most of
the complications of cardiac surgery<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.</p><p>Several cardioplegia solutions exist with different compositions. However, there is
no standard for the optimal composition and delivery technique<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Blood cardioplegia (BC),
which is the mixture of the subject's oxygenated blood (80%) and a crystalloid
solution (20%), is the most widely used cardioplegia type<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. The del Nido solution was
formulated by researchers from the University of Pittsburgh (Pittsburgh, PA, USA) in
the early 1990s<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.
As a calcium-free, hyperkalemic, modified depolarizing solution, it was specifically
formulated for paediatric cardiac surgery<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. The del Nido solution contains a base solution of
Plasma-Lyte and a crystalloid component. The use of solutions has started to
increase in recent years for adults. A recent meta-analysis demonstrated significant
advantages of the del Nido solution over BC in adults for several
parameters<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. However, the data regarding the use of del Nido solution in
combined coronary artery bypass grafting (CABG) and mitral valve replacement are
limited. The aim of the present study is to compare the del Nido cardioplegia (DNC)
with BC in CABG combined with mitral valve replacement surgery.</p></sec><sec sec-type="methods"><title>METHODS</title><p>A 3-year retrospective cohort study was performed in a single tertiary academic
center, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, between December
2014 and December 2017. The study protocol was approved by the same hospital's
ethics board.</p><p>Subjects in all age groups who underwent combined CABG (up to triple bypass) and
mitral stenosis surgery were included in the study. Exclusion criteria were as
follows:</p><p><list list-type="bullet"><list-item><p>Previous cardiac surgery (open)</p></list-item><list-item><p>Aortic insufficiency</p></list-item><list-item><p>Concomitant procedures (<italic>e.g</italic>., aortic annulus
enlargement, ascending aorta replacement, more than single-valve
surgery)</p></list-item><list-item><p>Tricuspid annuloplasty</p></list-item><list-item><p>Subjects who underwent 4 or more bypass grafts performed during CABG
surgery</p></list-item></list></p><p>The following demographic data and preoperative parameters were included: the
subject's age, gender, New York Heart Association (NYHA) functional status, smoking
and alcohol consumption status, body mass index, and comorbid diseases
(hypertension, dyslipidaemia, diabetes mellitus, chronic obstructive pulmonary
disease, and renal insufficiency). The preoperative previous stroke status,
preoperative cardiac rhythm (atrial fibrillation, sinus rhythm, etc.), and
preoperative echocardiogram parameters (ejection fraction [EF], valve
area, valve gradient, presence/absence of atrial thrombus, and valve insufficiency)
were also noted. For the study period, subjects who met the inclusion criteria for
the DNC group were compared with the same number of subjects who had previously
received BC by the same surgeon and met the inclusion criteria as well.</p><sec><title>Composition of del Nido and Blood Cardioplegia Solutions</title><p>Del Nido solution is composed of mixed blood and Plasma-Lyte A (1:4) (total
volume: 1060 mL). Mannitol (3.26 g), potassium chloride (K, 26 mEq), magnesium
sulphate (Mg, 2 g), lidocaine (130 mg), and sodium bicarbonate (13 mEq) were
added to the del Nido solution. BC solution consists of mixed blood and Ringer's
lactate (1:4) (total volume: 550 mL). Mannitol (10 g), potassium chloride (K, 46
mEq), magnesium sulphate (2.5 g), lidocaine (40 mg), and sodium bicarbonate (1
mEq) were added to the BC solution.</p></sec><sec><title>Surgical Procedure</title><p>All subjects underwent a full sternotomy for surgical access under
transoesophageal echocardiogram guidance. Cardioplegia solution was delivered by
antegrade cardioplegia cannula. The velocity was 200 mL/min and the solution's
temperature was between 8-14 C degrees. The BC (1000 mL) solution was
administered antegradely every 15 to 20 minutes. A single dose (1000 mL) of the
del Nido solution was administered antegradely. After the surgeon completed the
distal coronary anastomoses, a left atriotomy was performed to expose and excise
the mitral valve. The annulus of the mitral valve was sized, and the prosthesis
was sutured to the annulus with 25 coated, braided polyester stitches. The
correct positioning was confirmed and the left atrium was closed in the standard
fashion. The de novo mitral valve competency was assessed using transoesophageal
echocardiography. Once the competency of the valve was confirmed, the
cross-clamp was removed. A proximal coronary anastomosis was performed with a
side clamp. After the surgery, the subjects were transferred to the intensive
care unit and they were extubated 6-8 hours postoperatively. None of the
subjects with preoperative atrial fibrillation underwent a maze procedure.</p><p>The intraoperative parameters were recorded, including aortic clamp time, CPB
time, cardioplegia volume, bypass graft number, use of intraoperative
defibrillation, and use of inotropic support (adrenalin/other).</p><p>Creatine kinase-MB (CK-MB) and troponin T, blood count (fresh frozen plasma
[FFP], red blood cells [RBCs], and thrombocytes),
and blood creatinine levels were assessed at 1, 6, 12, and 24 hours
postoperatively. Haemoglobin (Hgb), haematocrit (Htc), glucose, and K levels
were assessed at 6 and 12 hours postoperatively.</p><p>Complications such as myocardial infarction, acute renal insufficiency, atrial
fibrillation, other arrhythmias, respiratory insufficiency, transient ischemic
attack (TIA)/stroke, the need for a pacemaker, reoperation due to haemorrhage,
infection, and death were noted.</p><p>The length of total intensive care and hospital stays was noted. All subjects
underwent an echocardiographic assessment for EF and valve function before
discharge from the hospital.</p></sec><sec><title>Statistical Analysis</title><p>The Number Cruncher Statistical System (NCSS) 2007 (Kaysville, Utah, USA) was
used for statistical analysis. Descriptive statistical methods (mean, standard
deviation [SD], median, frequency, ratio, minimum, and maximum)
were used. Quantitative data with normal distribution were compared using
Student's t-test, and the comparison of quantitative data without normal
distribution was performed using Mann-Whitney U test. Comparisons in groups for
data with normal distribution were performed using paired-samples t-test, and
comparisons in groups for data without normal distribution were performed using
Wilcoxon sign test. For qualitative data, Pearson's chi-square test, Fisher's
exact test, and Fisher-Freeman-Halton test were used. A <italic>P</italic>-value
less than 0.05 was considered significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>For the study period, 30 subjects met the inclusion criteria for the DNC group
(combined CABG [&#x02264; 3 bypass grafts] and mitral stenosis
surgery). The data were compared with 30 subjects who had previously received BC by
the same surgeon and met the inclusion criteria. Twenty-two subjects were excluded
from the study.</p><p>The subjects' baseline characteristics are presented in <xref rid="t1" ref-type="table">Table 1</xref>. The mean age of DNC and BC groups was 69.53&#x000b1;6.73
and 67.63&#x000b1;5.56 years, respectively, (<italic>P</italic>=0.272). The subjects
did not differ in terms of sex distribution (<italic>P</italic>=0.432), NYHA
functional status (<italic>P</italic>=1.000), or cardiac and non-cardiac
comorbidities. The groups also did not differ in preoperative echocardiographic
parameters. The preoperative EF (%) of DNC and BC groups was 48.63&#x000b1;5.61 and
47.20&#x000b1;7.36%, respectively, (<italic>P</italic>=0.400). The preoperative
valvular area in DNC and BC groups was 1.06&#x000b1;0.24 and 1.11&#x000b1;0.23
cm<sup>2</sup>, respectively, (<italic>P</italic>=0.376). And the preoperative
gradient (mmHg) for DNC and BC groups was 9.33&#x000b1;1.37 and 8.93&#x000b1;1.29,
respectively, (<italic>P</italic>=0.249).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Subjects baseline characteristics according to cardioplegia type.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="2">&#x000a0;</th><th align="center" colspan="2" rowspan="1">Cardioplegia type</th><th align="center" rowspan="2" colspan="1"><italic>P</italic></th></tr><tr><th align="left" rowspan="1" colspan="1">Del Nido (n=30)</th><th align="center" rowspan="1" colspan="1">Blood (n=30)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">54-81 (70)</td><td align="center" rowspan="1" colspan="1">54-80 (67)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN1">a</xref>0.272</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">69.53&#x000b1;6.73</td><td align="center" rowspan="1" colspan="1">67.63&#x000b1;5.56</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">11 (36.7)</td><td align="center" rowspan="1" colspan="1">14 (46.7)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN2">b</xref>0.432</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">19 (63.3)</td><td align="center" rowspan="1" colspan="1">16 (53.3)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="4" colspan="1">NYHA functional status</td><td align="left" rowspan="1" colspan="1">Class 1</td><td align="center" rowspan="1" colspan="1">2 (6.7)</td><td align="center" rowspan="1" colspan="1">2 (6.7)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN3">c</xref>1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Class 2</td><td align="center" rowspan="1" colspan="1">11 (36.7)</td><td align="center" rowspan="1" colspan="1">10 (33.3)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Class 3</td><td align="center" rowspan="1" colspan="1">15 (50)</td><td align="center" rowspan="1" colspan="1">15 (50)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Class 4</td><td align="center" rowspan="1" colspan="1">2 (6.7)</td><td align="center" rowspan="1" colspan="1">3 (100)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" colspan="5" rowspan="1">Cardiac comorbidity</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;&#x000a0;&#x000a0;Hypertension</td><td align="center" rowspan="1" colspan="1">23 (76.7)</td><td align="center" rowspan="1" colspan="1">22 (73.3)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN2">b</xref>0.766</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;&#x000a0;&#x000a0;Dyslipidemia</td><td align="center" rowspan="1" colspan="1">18 (60)</td><td align="center" rowspan="1" colspan="1">16 (53.3)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN2">b</xref>0.602</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;&#x000a0;&#x000a0;Rhythm-atrial fibrillation</td><td align="center" rowspan="1" colspan="1">8 (26.7)</td><td align="center" rowspan="1" colspan="1">9 (30)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN2">b</xref>0.774</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;&#x000a0;&#x000a0;Mitral valve insufficiency</td><td align="center" rowspan="1" colspan="1">5 (16.7)</td><td align="center" rowspan="1" colspan="1">4 (13.3)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN4">d</xref>1.000</td></tr><tr><td align="left" colspan="5" rowspan="1">Non-cardiac comorbidity</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;&#x000a0;&#x000a0;Tobacco use</td><td align="center" rowspan="1" colspan="1">15 (50)</td><td align="center" rowspan="1" colspan="1">17 (56.7)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN2">b</xref>0.605</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;&#x000a0;&#x000a0;Alcohol consumption</td><td align="center" rowspan="1" colspan="1">4 (13.3)</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN4">d</xref>1.000</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;&#x000a0;&#x000a0;Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">16 (53.3)</td><td align="center" rowspan="1" colspan="1">12 (40)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN2">b</xref>0.301</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;&#x000a0;&#x000a0;Chronic obstructive pulmonary
disease</td><td align="center" rowspan="1" colspan="1">7 (23.3)</td><td align="center" rowspan="1" colspan="1">5 (16.7)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN2">b</xref>0.519</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;&#x000a0;&#x000a0;Chronic renal insufficiency</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1">2 (6.7)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN4">d</xref>1,000</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;&#x000a0;&#x000a0;Preoperative TIA or stroke</td><td align="center" rowspan="1" colspan="1">2 (6.7)</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN4">d</xref>1,000</td></tr><tr><td align="left" colspan="5" rowspan="1">Preoperative echocardiographic
parameters</td></tr><tr><td align="left" rowspan="2" colspan="1">&#x000a0;&#x000a0;&#x000a0;Preoperative ejection fraction (%)</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">35-60 (49)</td><td align="center" rowspan="1" colspan="1">30-55 (49)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN1">a</xref>0.400</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">48.63&#x000b1;5.61</td><td align="center" rowspan="1" colspan="1">47.20&#x000b1;7.36</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">&#x000a0;&#x000a0;&#x000a0;Preoperative valvular area
(cm<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">0,7-1,5 (1,1)</td><td align="center" rowspan="1" colspan="1">0.7-1.5 (1.1)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN1">a</xref>0.376</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">1.06&#x000b1;0.24</td><td align="center" rowspan="1" colspan="1">1.11&#x000b1;0.23</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">&#x000a0;&#x000a0;&#x000a0;Preoperative gradient (mm/HG)</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">7-12 (9)</td><td align="center" rowspan="1" colspan="1">7-12 (9)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN1">a</xref>0.249</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">9.33&#x000b1;1.37</td><td align="center" rowspan="1" colspan="1">8.93&#x000b1;1.29</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>a</label><p>Student-t test;</p></fn><fn id="TFN2"><label>b</label><p>Pearson chi-square test;</p></fn><fn id="TFN3"><label>c</label><p>Fisher-Freeman-Halton test;</p></fn><fn id="TFN4"><label>d</label><p>Fisher's exact test.</p></fn><fn id="TFN5"><p>NYHA=New York Heart Association; SD=standard deviation; TIA=transient
ischemic attack</p></fn></table-wrap-foot></table-wrap><p>The intraoperative data are presented in <xref rid="t2" ref-type="table">Table
2</xref>. The number of bypass grafts and mitral valve replacement types did not
differ between the groups (<italic>P</italic>=0.927 and <italic>P</italic>=0.100,
respectively). Compared with the BC group, the DNC group demonstrated significantly
lower cardioplegia volume (BC = 1130.00&#x000b1;194.1 mL and DNC =
884.33&#x000b1;156.8 mL, <italic>P</italic>=0.001), CPB time (DNC =
110.90&#x000b1;12.52 min and BC = 121.70&#x000b1;13.57 min, <italic>P</italic>=0.002)
(<xref ref-type="fig" rid="f1">Figure 1</xref>), aortic clamp time (DNC =
91.37&#x000b1;11.58 min and BC = 101.37&#x000b1;13.87 min, <italic>P</italic>=0.004)
(<xref ref-type="fig" rid="f2">Figure 2</xref>), and number of intraoperative
defibrillation procedures (DNC = 6 cases and BC = 21 cases,
<italic>P</italic>=0.001).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Intraoperative data according to cardioplegia type.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">&#x000a0;</th><th align="center" rowspan="2" colspan="1">&#x000a0;</th><th align="center" colspan="2" rowspan="1">Cardioplegia type</th><th align="center" rowspan="2" colspan="1"><italic>P</italic></th></tr><tr><th align="center" rowspan="1" colspan="1">Del Nido (n=30)</th><th align="center" rowspan="1" colspan="1">Blood (n=30)</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">No. bypass graft</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN8">c</xref>0.927</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">14 (46.7)</td><td align="center" rowspan="1" colspan="1">16 (53.3)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">13 (43.3)</td><td align="center" rowspan="1" colspan="1">11 (36.7)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Cardioplegia volume (mL)</td><td align="center" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">700-1350 (930)</td><td align="center" rowspan="1" colspan="1">1000-1500 (1000)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN9">e</xref>0.001<xref ref-type="table-fn" rid="TFN10">**</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">884.33&#x000b1;156.8</td><td align="center" rowspan="1" colspan="1">1130.00&#x000b1;194.1</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Cardiopulmonary bypass time (min)</td><td align="center" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">85-132 (112.5)</td><td align="center" rowspan="1" colspan="1">95-150 (120.5)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">a</xref>0.002<xref ref-type="table-fn" rid="TFN10">**</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">110.90&#x000b1;12.52</td><td align="center" rowspan="1" colspan="1">121.70&#x000b1;13.57</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Aortic clamp time (min)</td><td align="center" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">68-110 (90)</td><td align="center" rowspan="1" colspan="1">75-128 (105)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN6">a</xref>0.004<xref ref-type="table-fn" rid="TFN10">**</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">91.37&#x000b1;11.58</td><td align="center" rowspan="1" colspan="1">101.37&#x000b1;13.87</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" colspan="2" rowspan="1">Intraoperative defibrillation</td><td align="center" rowspan="1" colspan="1">6 (20)</td><td align="center" rowspan="1" colspan="1">21 (70)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN7">b</xref>0.001<xref ref-type="table-fn" rid="TFN10">**</xref></td></tr><tr><td align="left" rowspan="2" colspan="1">Mitral valve replacement type</td><td align="center" rowspan="1" colspan="1">Mechanic valve</td><td align="center" rowspan="1" colspan="1">7 (23.3)</td><td align="center" rowspan="1" colspan="1">13 (43.3)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN7">b</xref>0.100</td></tr><tr><td align="center" rowspan="1" colspan="1">Bioprosthetic valve</td><td align="center" rowspan="1" colspan="1">23 (76.7</td><td align="center" rowspan="1" colspan="1">17 (56.7)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><label>a</label><p>Student-t test;</p></fn><fn id="TFN7"><label>b</label><p>Pearson chi-square test;</p></fn><fn id="TFN8"><label>c</label><p>Fisher-Freeman-Halton test;</p></fn><fn id="TFN9"><label>e</label><p>Mann-Whitney U test</p></fn><fn id="TFN10"><label>**</label><p><italic>P</italic>&#x0003c;0.01; SD=standard deviation</p></fn></table-wrap-foot></table-wrap><p><fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Comparison of cardiopulmonary bypass time (min) between del Nido
cardioplegia and blood cardioplegia.</p></caption><graphic xlink:href="rbccv-33-05-0496-g01"/></fig></p><p><fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Comparison of aortic clamp time (min) between del Nido cardioplegia and
blood cardioplegia.</p></caption><graphic xlink:href="rbccv-33-05-0496-g02"/></fig></p><p>After surgery, the subjects were transferred to the intensive care unit. Biochemical
parameters for the first postoperative day are presented in <xref rid="t3" ref-type="table">Table 3</xref>. The CK-MB levels at 1 and 24 hours postoperatively were
significantly lower in the DNC group (DNC = 5.82&#x000b1;4.72 ng/mL and BC =
7.27&#x000b1;4.69 ng/mL, <italic>P</italic>=0.041, and DNC = 13.30&#x000b1;7.72 ng/mL
and BC = 17.53&#x000b1;7.26 ng/mL, respectively, <italic>P</italic>=0.001). The
troponin levels at 1 hour did not differ between the groups (DNC = 0.13&#x000b1;0.05
ng/mL and BC = 0.24&#x000b1;0.25 ng/mL,
<italic>P</italic>=<sup>e</sup><bold>0.</bold>099). The troponin levels at 24
hours postoperatively were significantly lower in the DNC group (DNC =
0.28&#x000b1;0.41 ng/mL and BC = 0.67&#x000b1;1.03 ng/mL, <italic>P</italic>=0.001).
The Hgb levels at 6 and 24 hours postoperatively were significantly higher in the
DNC group than in the BC group (10.99&#x000b1;1.81 g/dL <italic>vs</italic>.
9.80&#x000b1;1.28 g/dL, <italic>P</italic>=0.005, and 10.86&#x000b1;1.11 g/dL
<italic>vs</italic>. 9.94&#x000b1;0.79 g/dL,
<italic>P</italic>=<sup>a</sup><bold>0.</bold>001, respectively). The
postoperative Htc levels at 6 and 24 hours were significantly higher in the DNC
group than in the BC group (32.43&#x000b1;4.94 <italic>vs</italic>.29.10&#x000b1;3.75,
<italic>P</italic>=<sup>a</sup>0.005, and 32.33&#x000b1;3.02 <italic>vs</italic>.
29.60&#x000b1;2.36, <italic>P</italic>=0.001, respectively). The postoperative K
levels were lower in the DNC group than in the BC group at the first postoperative
hour (4.09&#x000b1;0.82 mM <italic>vs</italic>. 4.40&#x000b1;0.83 mM, respectively,
<italic>P</italic>=0.031), whereas the K levels at 24 hours postoperatively did
not differ between the groups (<italic>P</italic>=0.223). There was no significant
difference between the groups for inotropic support regardless of the inotropic
agent used (<italic>e.g</italic>., epinephrine or other inotropic agent)
(<italic>P</italic>=1.000 and <italic>P</italic>=0.542, respectively). The
postoperative creatinine levels at 24 hours
(<italic>P</italic>=<sup>e</sup><bold>0.</bold>847) and postoperative glucose
levels at 6 and 24 hours (<italic>P</italic>=0.564 and <italic>P</italic>=0.604,
respectively) did not differ between the groups.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Postoperative biochemical parameters according to cardioplegia type.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">&#x000a0;</th><th align="center" colspan="2" rowspan="1">Cardioplegia type</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th></tr><tr><th align="center" rowspan="1" colspan="1">Del Nido (n=30)</th><th align="center" rowspan="1" colspan="1">Blood (n=30)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Inotropic support in first 24 hours</td><td align="left" rowspan="1" colspan="1">Norepinephrine (n)</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN13">d</xref>1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Other inotropes (n)</td><td align="center" rowspan="1" colspan="1">6 (20)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN12">b</xref>0.542</td></tr><tr><td align="left" rowspan="2" colspan="1">CK-MB (ng/mL), 1<sup>st</sup> hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">2.4-25 (5.8)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.041*</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">7.27&#x000b1;4.69</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">CK-MB (ng/mL), 24<sup>th</sup> hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">9.1-50 (17.4)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.001**</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">17.53&#x000b1;7.26</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><bold>Difference</bold></td><td align="center" rowspan="1" colspan="1">10.27&#x000b1;5.14</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.004**</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><italic>P</italic></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN15">f</xref>0.001**</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Troponin T (ng/mL), 1<sup>st</sup>
hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">0.05-1.2 (0.16)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.099</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">0.24&#x000b1;0.25</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Troponin T (ng/mL), 24<sup>th</sup>
hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">0.1-6 (0.5)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.001**</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">0.67&#x000b1;1.03</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><bold>Difference</bold></td><td align="center" rowspan="1" colspan="1">0.44&#x000b1;0.87</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.001**</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><italic>P</italic></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN15">f</xref>0.001**</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Haemoglobin (g/dL), 6<sup>th</sup>
hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">7.9-12.1 (10)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN11">a</xref>0.005**</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">9.80&#x000b1;1.28</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Haemoglobin (g/dL), 24<sup>th</sup>
hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">8.7-11.7 (9.9)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN11">a</xref>0.001**</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">9.94&#x000b1;0.79</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><bold>Difference</bold></td><td align="center" rowspan="1" colspan="1">0.13&#x000b1;1.22</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.387</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><italic>P</italic></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN16">g</xref>0.554</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Haematocrit, 6<sup>th</sup> hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">24-36 (29)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN11">a</xref>0.005**</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">29.10&#x000b1;3.75</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Haematocrit, 24<sup>th</sup> hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">26-35 (29)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN11">a</xref>0.001**</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">29.60&#x000b1;2.36</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><bold>Difference</bold></td><td align="center" rowspan="1" colspan="1">0.50&#x000b1;3.60</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.457</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><italic>P</italic></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN16">g</xref>0.453</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Postoperative 24<sup>th</sup> hour
creatinine (mg/dL)</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">0.7-5.1 (1.05)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.847</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">1.44&#x000b1;1.15</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">K<sup>+</sup> (mM), 1<sup>st</sup>
hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">3.5-6.3 (4.1)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.031*</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">4.40&#x000b1;0.83</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">K<sup>+</sup> (mM), 24<sup>th</sup>
hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">3.4-6.4 (4.1)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.223</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">4.47&#x000b1;0.89</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><bold>Difference</bold></td><td align="center" rowspan="1" colspan="1">0.06&#x000b1;0.47</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.132</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><italic>P</italic></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN15">f</xref>0.591</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Glucose (mg/dL), 6<sup>th</sup> hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">85-296 (128)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.564</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">164.00&#x000b1;70.23</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Glucose (mg/dL), 24<sup>th</sup> hour</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">89-350 (125)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.604</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">176.60&#x000b1;81.23</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><bold>Difference</bold></td><td align="center" rowspan="1" colspan="1">12.60&#x000b1;33.65</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN14">e</xref>0.876</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"><italic>P</italic></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN15">f</xref>0.115</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN11"><label>a</label><p>Student-t test;</p></fn><fn id="TFN12"><label>b</label><p>Pearson chi-square test;</p></fn><fn id="TFN13"><label>d</label><p>Fisher's Exact test;</p></fn><fn id="TFN14"><label>e</label><p>Mann-Whitney U test;</p></fn><fn id="TFN15"><label>f</label><p>Wilcoxon Signed Ranks</p></fn><fn id="TFN16"><label>g</label><p>Paired Samples Test;</p></fn><fn id="TFN17"><label>*</label><p><italic>P</italic>&#x0003c;0.05;</p></fn><fn id="TFN18"><label>**</label><p><italic>P</italic>&#x0003c;0.01.</p></fn><fn id="TFN19"><p>CK-MB=creatine kinase-MB; SD=standard deviation</p></fn></table-wrap-foot></table-wrap><p>The intensive care unit intubation period (hours) was significantly lower in the BC
group (DNC = 8.13&#x000b1;12.21 and BC = 6.82&#x000b1;1.57, <italic>P</italic>=0.037);
however, the intensive care unit stay (days) was not different between the groups
(<italic>P</italic>=0.163) (<xref rid="t4" ref-type="table">Table 4</xref>).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Postoperative data according to cardioplegia type.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">&#x000a0;</th><th align="center" colspan="2" rowspan="1">Cardioplegia type</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th></tr><tr><th align="center" rowspan="1" colspan="1">Del Nido (n=30)</th><th align="center" rowspan="1" colspan="1">Blood (n=30)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">Postoperative red blood cell transfusion
(n)</td><td align="left" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">18 (60)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN21">c</xref>0.754</td></tr><tr><td align="left" rowspan="1" colspan="1">1 unit</td><td align="center" rowspan="1" colspan="1">7 (23.3)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">2 units</td><td align="center" rowspan="1" colspan="1">2 (6.7)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">3 units</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="4" colspan="1">Postoperative plasma transfusion (n)</td><td align="left" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">16 (53.3)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN21">c</xref>0.001<xref ref-type="table-fn" rid="TFN25">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">1 unit</td><td align="center" rowspan="1" colspan="1">7 (23.3)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">2 units</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">3 units</td><td align="center" rowspan="1" colspan="1">4 (13.3)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="4" colspan="1">Postoperative platelet transfusion (n)</td><td align="left" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">27 (90)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN21">c</xref>0.611</td></tr><tr><td align="left" rowspan="1" colspan="1">1 unit</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">2 units</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">3 units</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="10" colspan="1">Complications</td><td align="left" rowspan="1" colspan="1">Low cardiac output syndrome</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN22">d</xref>1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="center" rowspan="1" colspan="1">1 (3.3)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN22">d</xref>1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute renal insufficiency</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN22">d</xref>1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">8 (26.7)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN20">b</xref>0.095</td></tr><tr><td align="left" rowspan="1" colspan="1">Respiratory failure</td><td align="center" rowspan="1" colspan="1">4 (13.3)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN22">d</xref>0.671</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke/TIA</td><td align="center" rowspan="1" colspan="1">1 (3.3)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN22">d</xref>1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Permanent pacemaker</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Reoperation for bleeding</td><td align="center" rowspan="1" colspan="1">3 (10)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN22">d</xref>1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Infection</td><td align="center" rowspan="1" colspan="1">1 (3.3)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN22">d</xref>1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital mortality</td><td align="center" rowspan="1" colspan="1">1 (3.3)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN22">d</xref>1.000</td></tr><tr><td align="left" rowspan="2" colspan="1">Intensive care unit intubation period
(hours)</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">5-11 (6.5)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN23">e</xref>0.037<xref ref-type="table-fn" rid="TFN24">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">6.82&#x000b1;1.57</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Intensive care unit stay (days)</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">2-10 (2)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN23">e</xref>0.163</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">2.53&#x000b1;1.57</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Hospital stay (days)</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">5-10 (6)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN23">e</xref>0.142</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">6.30&#x000b1;1.58</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Pre-discharge ejection fraction (%)</td><td align="left" rowspan="1" colspan="1">Min-max (median)</td><td align="center" rowspan="1" colspan="1">30-55 (45)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN23">e</xref>0.005<xref ref-type="table-fn" rid="TFN25">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">45.72&#x000b1;5.86</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN20"><label>b</label><p>Pearson chi-square test;</p></fn><fn id="TFN21"><label>c</label><p>Fisher Freeman Halton Test;</p></fn><fn id="TFN22"><label>d</label><p>Fisher's Exact test;</p></fn><fn id="TFN23"><label>e</label><p>Mann-Whitney U test;</p></fn><fn id="TFN24"><label>*</label><p><italic>P</italic>&#x0003c;0.05;</p></fn><fn id="TFN25"><label>**</label><p><italic>P</italic>&#x0003c;0.01.</p></fn><fn id="TFN26"><p>SD=standard deviation; TIA=transient ischemic attack</p></fn></table-wrap-foot></table-wrap><p>The need for postoperative transfusion of RBCs or platelets did not differ between
the groups (<italic>P</italic>=0.754 and <italic>P</italic>=0.611, respectively).
The postoperative plasma transfusion rate was significantly higher in the DNC group
than in the BC group (<italic>P</italic>=0.001). Regarding complications, 17 events
occurred in the DNC group and 25 events occurred in the BC group. All the
comparisons for postoperative complications were not statistically significant.</p><p>At pre-discharge echocardiography, the DNC group demonstrated a significantly better
EF percentage than the BC group (47.79&#x000b1;5.50 <italic>vs</italic>.
45.72&#x000b1;5.86, respectively, <italic>P</italic>=0.005). The length of hospital
stay was not different between the groups (<italic>P</italic>=0.142).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>During heart surgery, myocardial protection is an important consideration. Several
cardioplegia solutions are available; however, there is no consensus concerning the
optimal composition or technique<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. The current study compared the safety and efficacy of
DNC and BC in 30 matched subjects. Compared with the BC group, the DNC group
demonstrated better intraoperative parameters, including lower cardioplegia volume,
CPB time, aortic clamp time, and need for intraoperative defibrillation.</p><p>Common cardioplegia techniques include BC, histidine-tryptophan-ketoglutarate
solution, and DNC<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.
The del Nido solution contains Plasma-Lyte A and a crystalloid component. The base
solution has the same electrolyte composition as extracellular fluid, and the
crystalloid component contains mannitol, magnesium sulphate, sodium bicarbonate,
potassium chloride, and lidocaine<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Lidocaine (Na<sup>+</sup> channel blocker) and
Mg<sup>2+</sup> (Ca<sup>2+</sup> competing agent/Ca<sup>2+</sup> channel
blocker) decrease intracellular Ca<sup>2+</sup> concentration, myocardial
excitability, cellular metabolism, and energy consumption<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Although originally designed for a child's immature
heart, the del Nido solution is offered as a new alternative to protect the
ischaemic myocardium<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>Available literature did not demonstrate homogeneous data regarding DNC. However,
initial experiences demonstrated its safety in CABG and isolated or combined valve
surgery<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.
The use of DNC in CABG has been addressed in a few studies. Guajardo Salinas et
al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>
compared DNC (n=134) with BC (n=230). Except for the mean cardioplegia volume, mean
number of cardioplegia doses, and defibrillation after cross-clamp removal, the
groups demonstrated similar intraoperative and postoperative properties. The use of
DNC resulted in a lower need for defibrillation in the subjects who underwent CABG.
An equivalent efficiency of DNC was previously demonstrated by Timek et
al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>, who
reported the results for 100 propensity-score-matched subjects who underwent CABG.
The use of DNC resulted in lower glucose levels than those for BC. In a previous
report, Yerebakan et al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> demonstrated the safety of DNC in high-risk CABG
surgery after acute myocardial infarction. Of 48 subjects who received DNC, the
authors reported significantly shorter mean CPB and cross-clamp times; however,
other intraoperative and postoperative data were similar between the groups.</p><p>Among the studies that addressed the use of DNC in mitral valve surgery, Yammine et
al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>
compared modified DNC with whole BC in 79 matched subjects. The included subjects
underwent valve procedures and/or CABG or mechanical valve implant. The
postoperative 24-hour CK-MB levels were high in the DNC group. Except for the CK-MB
levels, the operative parameters and postoperative comparisons were similar in both
groups. Kim et al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> compared the use of DNC with BC in 39 matched subjects.
Although most of the subjects underwent isolated valvular surgery, other subjects
who underwent aortic replacement surgery, CABG surgery, or had a congenital heart
disease or tumour were also enrolled in the study. They've found no association
between peak troponin I levels and left ventricular mass/aortic clamp time between
the groups. Mick et al.<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup> compared the use of DNC with Buckberg cardioplegia in
isolated aortic (n=85) or mitral valve surgery (n=110). The results demonstrated the
safety of DNC in adult subjects who underwent isolated valve surgery. In aortic
valve surgery, the use of DNC significantly reduced aortic clamp time, bypass time,
and operating room time; however, in mitral valve surgery, the use of DNC was found
to only be advantageous in case of postoperative insulin need. In both groups, the
postoperative troponin levels as well as the left ventricular EF were similar.</p><p>Aortic valve procedures were also addressed in studies. Sorabella et
al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>
compared the use of DNC (n=52) with BC (n=65) in isolated aortic valve procedures.
Except for total cardioplegia volume, no significant difference was found between
the groups. Of 54 matched subjects, Ota et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> reported shorter CPB and cross-clamp times
when DNC was used. Postoperative complications as well as length of intensive care
and hospital stays did not differ between the groups. Vistarini et
al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>
reported less atrial fibrillation, lower CK-MB levels, and lower insulin requirement
associated with the use of DNC in minimally invasive aortic valve surgery. Hamad et
al.<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>
evaluated the effect of DNC in CABG combined with aortic valve surgery in 25
subjects. CPB time, cross-clamp time, and postoperative CK-MB and troponin levels
were lower in the surgeries with use of DNC.</p><p>The basic advantages of DNC are single-dose application and glucose-free
ingredients<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. DNC was administered as a single dose for subjects who
underwent procedures of less than 90 minutes duration. The single-dose application
decreased CPB and cross-clamp times. A recent meta-analysis involving 9 studies
reported the effect of DNC in 1501 subjects (4 studies involved isolated valve
procedures, 3 studies involved CABG procedures, and 2 studies reported valve
procedures or CABG). The results of the meta-analysis reported shorter CPB and
cross-clamp times when DNC was used<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Cardioplegia volume, blood glucose levels,
ventilation time, and length of intensive care stay were also decreased for DNC when
compared with those for BC. BC requires multiple interruptions, which is an
additional factor for ischaemic damage. The single-dose application was associated
with a lower cardioplegia volume and less haemodilution, which decreases the
transfusion requirement according to literature<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. In
the present study, the need for RBCs and platelet transfusion rates were similar in
DNC and BC groups. Although the postoperative plasma transfusion need was lower in
the BC group, the importance of this finding could not be clearly described. Having
glucose-free ingredients in the solution is important for subjects who have diabetes
mellitus. However, no significant difference was observed between the groups in the
present study.</p><p>The use of DNC demonstrated lower CK-MB and troponin levels, which are sensitive
biomarkers for cardiac injury. The lower levels in our study were a sign of better
myocardial protection. The DNC group also demonstrated higher Hgb and Htc levels;
however, RBC transfusion rates were similar for both groups. In the present study,
the use of DNC demonstrated similar postoperative complication rates and intensive
care and hospital stay rates. Although the BC group demonstrated significantly
shorter intensive care unit intubation period than the DNC group, this difference
was not regarded as clinically significant. Before discharge, the subjects underwent
an echocardiographic assessment. A higher EF rate in the DNC group was also a sign
of better myocardial protection.</p><p>This study presents a single-center, single-surgeon experience in a retrospective
design, and there are limitations related to such design. Long-term follow-up was
not conducted, which made it difficult to interpret some findings such as lower
cardiac marker levels and better postoperative EF rates. As an initial experience,
our data added observational value, but there is a need for randomised, multicenter
trials comparing different solutions in different cardiac procedures.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The current study results showed better intraoperative and postoperative chemical
parameters when DNC was used. The need for a lower cardioplegia volume and an
uninterrupted procedure are the main advantages of DNC. DNC is at least equivalent
to BC and it is a safe alternative to BC in CABG combined with mitral valve surgery
in adults.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AAK</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">ST</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published; agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and
resolved</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Department of Cardiovascular Surgery, Bakirkoy Dr.
Sadi Konuk Training and Research Hospital, Istanbul, Turkey.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ack><title>ACKNOWLEDGEMENTS</title><p>We would like to thank Emire Bor (Empiar Statistics) for performing the statistical
analysis of the study.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Del Nido cardioplegia for myocardial protection in adult cardiac
surgery: a systematic review and meta-analysis</article-title><source>ASAIO J</source><year>2018</year><volume>64</volume><issue>3</issue><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">28863040</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hamad</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Lalibert&#x000e9;</surname><given-names>&#x000c9;</given-names></name><name><surname>Bouchard</surname><given-names>D</given-names></name><name><surname>Lamarche</surname><given-names>Y</given-names></name><name><surname>El-Hamamsy</surname><given-names>I</given-names></name><etal/></person-group><article-title>Comparison of del Nido cardioplegia with blood cardioplegia in
adult combined surgery</article-title><source>Innovations</source><publisher-loc>Phila</publisher-loc><year>2017</year><volume>12</volume><issue>5</issue><fpage>356</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">29016380</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorjipour</surname><given-names>F</given-names></name><name><surname>Dehaki</surname><given-names>MG</given-names></name><name><surname>Totonchi</surname><given-names>Z</given-names></name><name><surname>Hajimiresmaiel</surname><given-names>SJ</given-names></name><name><surname>Azarfarin</surname><given-names>R</given-names></name><name><surname>Pazoki-Toroudi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Inflammatory cytokine response and cardiac troponin I changes in
cardiopulmonary bypass using two cardioplegia solutions; del Nido and
modified St. Thomas': a randomized controlled trial</article-title><source>Perfusion</source><year>2017</year><volume>32</volume><issue>5</issue><fpage>394</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">28152655</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ad</surname><given-names>N</given-names></name></person-group><article-title>Del Nido cardioplegia: ready for prime time in adult cardiac
surgery?</article-title><source>J Thorac Cardiovasc Surg</source><year>2015</year><volume>149</volume><issue>2</issue><fpage>637</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">25726885</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matte</surname><given-names>GS</given-names></name><name><surname>Nido</surname><given-names>PJ del</given-names></name></person-group><article-title>History and use of del Nido cardioplegia solution at Boston
Children's Hospital</article-title><source>J Extra Corpor Technol</source><year>2012</year><volume>44</volume><issue>3</issue><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">23198389</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Ball</surname><given-names>C</given-names></name><name><surname>Grady</surname><given-names>P</given-names></name><name><surname>Mick</surname><given-names>S</given-names></name></person-group><article-title>Use of del Nido cardioplegia for adult cardiac surgery at the
Cleveland Clinic: perfusion implications</article-title><source>J Extra Corpor Technol</source><year>2014</year><volume>46</volume><issue>4</issue><fpage>317</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">26357803</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yammine</surname><given-names>M</given-names></name><name><surname>Neely</surname><given-names>RC</given-names></name><name><surname>Loberman</surname><given-names>D</given-names></name><name><surname>Rajab</surname><given-names>TK</given-names></name><name><surname>Grewal</surname><given-names>A</given-names></name><name><surname>McGurk</surname><given-names>S</given-names></name><etal/></person-group><article-title>The use of lidocaine containing cardioplegia in surgery for adult
acquired heart disease</article-title><source>J Card Surg</source><year>2015</year><volume>30</volume><issue>9</issue><fpage>677</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">26198086</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourmoghadam</surname><given-names>KK</given-names></name><name><surname>Ruzmetov</surname><given-names>M</given-names></name><name><surname>O'Brien</surname><given-names>MC</given-names></name><name><surname>Piggott</surname><given-names>KD</given-names></name><name><surname>Plancher</surname><given-names>G</given-names></name><name><surname>Narasimhulu</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Comparing del Nido and conventional cardioplegia in infants and
neonates in congenital heart surgery</article-title><source>Ann Thorac Surg</source><year>2017</year><volume>103</volume><issue>5</issue><fpage>1550</fpage><lpage>1556</lpage><pub-id pub-id-type="pmid">28190549</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salinas</surname><given-names>GE Guajardo</given-names></name><name><surname>Nutt</surname><given-names>R</given-names></name><name><surname>Rodriguez-Araujo</surname><given-names>G</given-names></name></person-group><article-title>Del Nido cardioplegia in low risk adults undergoing first time
coronary artery bypass surgery</article-title><source>Perfusion</source><year>2017</year><volume>32</volume><issue>1</issue><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">27451052</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timek</surname><given-names>T</given-names></name><name><surname>Willekes</surname><given-names>C</given-names></name><name><surname>Hulme</surname><given-names>O</given-names></name><name><surname>Himelhoch</surname><given-names>B</given-names></name><name><surname>Nadeau</surname><given-names>D</given-names></name><name><surname>Borgman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Propensity matched analysis of del Nido cardioplegia in adult
coronary artery bypass grafting: initial experience with 100 consecutive
patients</article-title><source>Ann Thorac Surg</source><year>2016</year><volume>101</volume><issue>6</issue><fpage>2237</fpage><lpage>2241</lpage><pub-id pub-id-type="pmid">27016843</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yerebakan</surname><given-names>H</given-names></name><name><surname>Sorabella</surname><given-names>RA</given-names></name><name><surname>Najjar</surname><given-names>M</given-names></name><name><surname>Castillero</surname><given-names>E</given-names></name><name><surname>Mongero</surname><given-names>L</given-names></name><name><surname>Beck</surname><given-names>J</given-names></name><etal/></person-group><article-title>Del Nido cardioplegia can be safely administered in high-risk
coronary artery bypass grafting surgery after acute myocardial infarction: a
propensity matched comparison</article-title><source>J Cardiothorac Surg</source><year>2014</year><volume>9</volume><fpage>141</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">25359427</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Jeong</surname><given-names>JH</given-names></name><name><surname>Moon</surname><given-names>SJ</given-names></name><name><surname>Ahn</surname><given-names>H</given-names></name><name><surname>Hwang</surname><given-names>HY</given-names></name></person-group><article-title>Sufficient myocardial protection of del Nido cardioplegia
regardless of ventricular mass and myocardial ischemic time in adult cardiac
surgical patients</article-title><source>J Thorac Dis</source><year>2016</year><volume>8</volume><issue>8</issue><fpage>2004</fpage><lpage>2010</lpage><pub-id pub-id-type="pmid">27621853</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mick</surname><given-names>SL</given-names></name><name><surname>Robich</surname><given-names>MP</given-names></name><name><surname>Houghtaling</surname><given-names>PL</given-names></name><name><surname>Gillinov</surname><given-names>AM</given-names></name><name><surname>Soltesz</surname><given-names>EG</given-names></name><name><surname>Johnston</surname><given-names>DR</given-names></name><etal/></person-group><article-title>del Nido versus Buckberg cardioplegia in adult isolated valve
surgery</article-title><source>J Thorac Cardiovasc Surg</source><year>2015</year><volume>149</volume><issue>2</issue><fpage>626</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">25483897</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorabella</surname><given-names>RA</given-names></name><name><surname>Akashi</surname><given-names>H</given-names></name><name><surname>Yerebakan</surname><given-names>H</given-names></name><name><surname>Najjar</surname><given-names>M</given-names></name><name><surname>Mannan</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Myocardial protection using del Nido cardioplegia solution in
adult reoperative aortic valve surgery</article-title><source>J Card Surg</source><year>2014</year><volume>29</volume><issue>4</issue><fpage>445</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">24861160</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ota</surname><given-names>T</given-names></name><name><surname>Yerebakan</surname><given-names>H</given-names></name><name><surname>Neely</surname><given-names>RC</given-names></name><name><surname>Mongero</surname><given-names>L</given-names></name><name><surname>George</surname><given-names>I</given-names></name><name><surname>Takayama</surname><given-names>H</given-names></name><etal/></person-group><article-title>Short-term outcomes in adult cardiac surgery in the use of del
Nido cardioplegia solution</article-title><source>Perfusion</source><year>2016</year><volume>31</volume><issue>1</issue><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">26228274</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vistarini</surname><given-names>N</given-names></name><name><surname>Lalibert&#x000e9;</surname><given-names>E</given-names></name><name><surname>Beauchamp</surname><given-names>P</given-names></name><name><surname>Bouhout</surname><given-names>I</given-names></name><name><surname>Lamarche</surname><given-names>Y</given-names></name><name><surname>Cartier</surname><given-names>R</given-names></name><etal/></person-group><article-title>Del Nido cardioplegia in the setting of minimally invasive aortic
valve surgery</article-title><source>Perfusion</source><year>2017</year><volume>32</volume><issue>2</issue><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">27469246</pub-id></element-citation></ref></ref-list></back></article>